MedWatch

Researchers behind Alzheimer's study: GLP-1 drugs show great promise

Armed with data from a phase II trial testing the efficiency of Novo Nordisk's liraglutide on Alzheimer's patients, scientists say the given drug class shows great promise for combating the disease – even though the market shows disappointment on Novo's behalf.

Photo: George Frey/Reuters/Ritzau Scanpix

Few ailments have frustrated medical science and the pharmaceutical industry for years on end in the way Alzheimer's has, as many have tried – and failed – to develop just one efficient treatment for the disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs